Lennox Hodgkinson of Nova Scotia was dressed all in Blackhawks gear for what his dad described as ...
BRIDGEWATER, N.J. - Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company with a market capitalization of $14.57 ...
The Bridgewater, N.J., biopharmaceutical company said brensocatib has the potential to become the first and only approved treatment for non-cystic fibrosis bronchiectasis, which causes the lungs' ...
When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...
Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...
By the time Enid Katz was two years old, she had already suffered through several bouts of bronchitis and was always hungry, ...
Insmed (INSM) announced that the U.S. FDA has accepted the company’s New Drug Application for brensocatib for patients with non-cystic fibrosis ...
Sionna Therapeutics hopes to raise $150 million and secure a market capitalization of about $692 million in an initial public ...
The US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for brensocatib for patients with ...
If you receive a denial letter from your insurer, don’t appeal the decision before seeking legal advice, says a leading ...